Research programme: antibody therapeutics - Xencor

Drug Profile

Research programme: antibody therapeutics - Xencor

Alternative Names: PD1 x costim bispecific antibodies - Xencor; PD1 x costimulation bispecific antibodies - Xencor; XmAb 14484; XmAb 22841; XmAb 23104; XmAb 24306; XmAb 5483; XmAb bispecific x4; XmAb®5485

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD20 antigen inhibitors; CD20 antigen modulators; CD3 antigen inhibitors; CD3 antigen modulators; CD38 antigen inhibitors; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3-receptor-alpha-subunit-antagonists; Programmed cell death-1 receptor antagonists; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; B cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Research Immunological disorders

Most Recent Events

  • 21 Apr 2018 Preclinical pharmacodynamics data in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 28 Feb 2018 Xencor has patent protection for XmAb 20717, XmAb 22841 and XmAb 23104 in USA and other countries worldwide
  • 05 Jan 2018 Xencor plans a phase I trial of XmAb 20717 for Solid Tumours (Late stage disease) in August 2018 (IV) (NCT03517488)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top